A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma
Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplantation 2004, 34: 175-179. PMID: 15170171, DOI: 10.1038/sj.bmt.1704551.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsB-LymphocytesBone Marrow PurgingCytarabineFemaleHematopoietic Stem Cell MobilizationHumansImmunophenotypingLymphoma, FollicularLymphoma, Mantle-CellMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRituximabSalvage TherapyTransplantation, AutologousConceptsB-cell depletionHD cytarabineB cellsCell lymphomaPeripheral blood stem cell mobilizationBlood stem cell mobilizationRefractory mantle cell lymphomaHigh-dose AraCRefractory follicular lymphomaHigh-dose cytarabineCombination of rituximabGranulocyte colony-stimulating factorCollection of PBSCStem cell mobilizationMantle cell lymphomaColony-stimulating factorHD chemotherapyPeripheral CD19Concurrent administrationIndolent lymphomaPeripheral bloodPatients PCRProfound depletionCell mobilizationMedian number